Moderna, Inc. - Understand $mrna stock

$MRNA Market Cap: $16.02 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$5.081B

TTM

Gross Margin

58.54%

TTM

Net Earnings

-$2.224B

TTM

Current Assets

$9.666B

Q3 2024

Current Liabilities

$2.201B

Q3 2024

Current Ratio

439.16%

Q3 2024

Total Assets

$15.80B

Q3 2024

Total Liabilities

$3.876B

Q3 2024

Book Value

$11.93B

Q3 2024

Cash

$1.644B

Q3 2024

P/E

-7.203

Nov 29, 2024 EST

Free Cash Flow

-$3.956B

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$6.848B	$19.26B	$18.47B	$803.0M	$60.00M	$135.1M	$205.8M	$108.4M
YoY Change	-64.45%	4.29%	2200.25%	1238.33%	-55.58%	-34.38%	89.88%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$6.848B	$19.26B	$18.47B	$803.0M	$60.00M	$135.1M	$205.8M	$108.4M
Cost Of Revenue	$4.693B	$5.416B	$2.617B	$8.000M	$0.00	$0.00
Gross Profit	$2.155B	$13.85B	$15.85B	$795.0M	$60.00M	$135.1M
Gross Profit Margin	31.47%	71.88%	85.83%	99.0%	100.0%	100.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Selling, General & Admin	$1.549B	$1.132B	$567.0M	$188.3M	$109.6M	$94.30M	$64.70M	$57.50M
YoY Change	36.84%	99.65%	201.12%	71.81%	16.22%	45.75%	12.52%
% of Gross Profit	71.88%	8.18%	3.58%	23.69%	182.67%	69.82%
Research & Development	$4.845B	$3.295B	$1.991B	$1.370B	$496.0M	$454.1M	$410.5M	$274.7M
YoY Change	47.04%	65.49%	45.33%	176.21%	9.23%	10.63%	49.41%
% of Gross Profit	224.83%	23.8%	12.56%	172.33%	826.67%	336.19%
Depreciation & Amortization	$617.0M	$348.0M	$232.0M	$31.00M	$31.00M	$24.90M	$20.50M	$15.11M
YoY Change	77.3%	50.0%	648.39%	0.0%	24.5%	21.46%	35.64%
% of Gross Profit	28.63%	2.51%	1.46%	3.9%	51.67%	18.44%
Operating Expenses	$4.845B	$3.295B	$1.991B	$1.370B	$605.9M	$548.3M	$475.2M	$332.2M
YoY Change	47.04%	65.49%	45.33%	126.1%	10.5%	15.39%	43.05%
Operating Profit	-$4.239B	$9.420B	$13.30B	-$763.0M	-$546.0M	-$413.3M	-$269.4M	-$223.8M
YoY Change	-145.0%	-29.15%	-1842.6%	39.74%	32.12%	53.43%	20.37%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Interest Expense	$421.0M	$151.0M	$1.000M	$16.10M	$32.20M	$24.00M	$13.40M	$8.600M
YoY Change	178.81%	15000.0%	-93.79%	-50.0%	34.17%	79.1%	55.81%
% of Operating Profit		1.6%	0.01%
Other Income/Expense, Net	-$124.0M	-$45.00M	-$29.00M	-$6.000M	-$8.000M	$1.835M	-$1.875M	-$2.709M
YoY Change	175.56%	55.17%	383.33%	-25.0%	-535.97%	-197.87%	-30.79%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Pretax Income	-$3.942B	$9.575B	$13.29B	-$744.0M	-$515.0M	-$380.5M	-$247.8M	-$211.8M
YoY Change	-141.17%	-27.93%	-1885.62%	44.47%	35.36%	53.55%	17.0%
Income Tax	$772.0M	$1.213B	$1.083B	$3.000M	-$1.000M	$326.0K	-$80.00K	$1.043M
% Of Pretax Income		12.67%	8.15%
Net Earnings	-$4.714B	$8.362B	$12.20B	-$747.0M	-$514.0M	-$384.7M	-$255.9M	-$216.2M
YoY Change	-156.37%	-31.47%	-1733.47%	45.33%	33.6%	50.35%	18.36%
Net Earnings / Revenue	-68.84%	43.41%	66.06%	-93.03%	-856.67%	-284.84%	-124.33%	-199.46%
Basic Earnings Per Share	-$12.33	$21.26	$30.31	-$1.96	-$1.55
Diluted Earnings Per Share	-$12.33	$20.12	$28.29	-$1.96	-$1.55	-$1.170M	-$788.8K	-$666.5K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Short-Term Investments	$8.604B	$9.902B	$10.73B	$4.608B	$1.103B	$1.521B	$756.0M	$1.058B
YoY Change	-13.11%	-7.69%	132.81%	317.73%	-27.5%	101.24%	-28.55%
Cash & Equivalents	$2.907B	$3.205B	$6.848B	$2.624B	$235.9M	$658.4M	$134.9M	$50.10M
Short-Term Investments	$5.697B	$6.697B	$3.879B	$1.984B	$867.1M	$863.1M	$621.2M	$1.008B
Other Short-Term Assets	$627.0M	$916.0M	$607.0M	$233.2M	$9.500M	$11.00M	$10.60M	$11.10M
YoY Change	-31.55%	50.91%	160.29%	2354.74%	-13.64%	3.77%	-4.5%
Inventory	$202.0M	$949.0M	$1.441B	$46.50M
Prepaid Expenses
Receivables	$892.0M	$1.385B	$3.175B	$1.391B	$5.400M	$12.60M	$13.40M	$13.50M
Other Receivables	$0.00	$279.0M	$121.0M	$19.90M	$10.90M	$18.00M	$3.300M	$4.500M
Total Short-Term Assets	$10.33B	$13.43B	$16.07B	$6.298B	$1.129B	$1.563B	$783.2M	$1.087B
YoY Change	-23.13%	-16.43%	155.18%	457.93%	-27.78%	99.57%	-27.96%
Property, Plant & Equipment	$2.658B	$2.139B	$1.383B	$387.1M	$287.9M	$212.0M	$139.0M	$81.20M
YoY Change	24.26%	54.66%	257.27%	34.46%	35.8%	52.52%	71.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$4.677B	$8.318B	$6.843B	$638.8M	$160.0M	$173.0M	$145.9M	$236.6M
YoY Change	-43.77%	21.55%	971.23%	299.25%	-7.51%	18.57%	-38.33%
Other Assets	$766.0M	$1.970B	$372.0M	$12.90M	$12.70M	$14.20M	$16.40M	$12.20M
YoY Change	-61.12%	429.57%	2783.72%	1.57%	-10.56%	-13.41%	34.43%
Total Long-Term Assets	$8.101B	$12.43B	$8.598B	$1.039B	$460.6M	$399.1M	$301.3M	$330.0M
YoY Change	-34.81%	44.53%	727.61%	125.55%	15.41%	32.46%	-8.7%
Total Assets	$18.43B	$25.86B	$24.67B	$7.337B	$1.589B	$1.962B	$1.085B	$1.417B
YoY Change
Accounts Payable	$520.0M	$487.0M	$302.0M	$18.40M	$7.100M	$31.20M	$20.70M	$28.20M
YoY Change	6.78%	61.26%	1541.3%	159.15%	-77.24%	50.72%	-26.6%
Accrued Expenses	$1.798B	$2.136B	$1.518B	$475.6M	$71.20M	$79.10M	$72.70M	$25.10M
YoY Change	-15.82%	40.71%	219.18%	567.98%	-9.99%	8.8%	189.64%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$161.0M	$165.0M	$24.30M
YoY Change	-100.0%	-2.42%	579.01%
Total Short-Term Liabilities	$3.015B	$4.923B	$9.128B	$4.389B	$143.1M	$222.8M	$191.5M	$162.8M
YoY Change	-38.76%	-46.07%	107.98%	2966.95%	-35.77%	16.34%	17.63%
Long-Term Debt	$575.0M	$912.0M	$599.0M	$109.9M	$38.70M	$33.50M	$15.70M	$12.50M
YoY Change	-36.95%	52.25%	445.04%	183.98%	15.52%	113.38%	25.6%
Other Long-Term Liabilities	$982.0M	$900.0M	$797.0M	$276.7M	$232.8M	$175.6M	$252.0M	$400.0M
YoY Change	9.11%	12.92%	188.04%	18.86%	32.57%	-30.32%	-37.0%
Total Long-Term Liabilities	$1.557B	$1.812B	$1.396B	$386.6M	$271.5M	$209.1M	$267.7M	$412.5M
YoY Change	-14.07%	29.8%	261.1%	42.39%	29.84%	-21.89%	-35.1%
Total Liabilities	$4.572B	$6.735B	$10.52B	$4.775B	$414.6M	$431.9M	$459.2M	$575.3M
YoY Change	-32.12%	-36.0%	120.38%	1051.81%	-4.01%	-5.95%	-20.18%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	382.0M shares	394.0M shares	403.0M shares	381.0M shares	331.0M shares
Diluted Shares Outstanding	382.0M shares	416.0M shares	431.0M shares	381.0M shares	331.0M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $16.02 Billion

About Moderna, Inc.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 5,600 full-time employees. The company went IPO on 2018-12-07. The firm is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). The company is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.

Industry: Biological Products, (No Diagnostic Substances) Peers: ALNYLAM PHARMACEUTICALS, INC. AMGEN INC BIOGEN INC. BIOMARIN PHARMACEUTICAL INC GILEAD SCIENCES, INC. REGENERON PHARMACEUTICALS, INC. Seagen Inc. VERTEX PHARMACEUTICALS INC / MA